What's positive about 'triple-negative' breast cancer? (Q37605859)

21 August 2017

1 reference

title

What's positive about 'triple-negative' breast cancer? (English)

1 reference

21 August 2017

Sara A Hurvitz

1

1 reference

PubMed ID

19792970

21 August 2017

Richard S Finn

series ordinal

2

1 reference

PubMed ID

19792970

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

21 August 2017

1 reference

21 August 2017

5

1 reference

21 August 2017

7

1 reference

21 August 2017

1015-1025

1 reference

21 August 2017

Cancer statistics, 2008

1 reference

Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis.

21 January 2018

1 reference

Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions.

21 January 2018

1 reference

Her2-positive breast cancer: herceptin and beyond.

21 January 2018

1 reference

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

21 January 2018

1 reference

Molecular portraits of human breast tumours

21 January 2018

1 reference

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

21 January 2018

1 reference

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression.

21 January 2018

1 reference

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer

21 January 2018

1 reference

Metaplastic breast carcinomas are basal-like tumours

21 January 2018

1 reference

Typical medullary breast carcinomas have a basal/myoepithelial phenotype.

21 January 2018

1 reference

Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.

21 January 2018

1 reference

How basal are triple-negative breast cancers?

21 January 2018

1 reference

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

21 January 2018

1 reference

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

21 January 2018

1 reference

Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes

21 January 2018

1 reference

Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance

21 January 2018

1 reference

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

Untangling the ErbB signalling network

21 January 2018

1 reference

Ligand-induced, receptor-mediated dimerization and activation of EGF receptor

21 January 2018

1 reference

Targeting the EGFR pathway for cancer therapy

21 January 2018

1 reference

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

EGFR-targeted therapies in lung cancer: predictors of response and toxicity

21 January 2018

1 reference

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

21 January 2018

1 reference

Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice

21 January 2018

1 reference

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

21 January 2018

1 reference

Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme

21 January 2018

1 reference

21 January 2018

The Hallmarks of Cancer

1 reference

The biology of VEGF and its receptors

21 January 2018

1 reference

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer

21 January 2018

1 reference

New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.

21 January 2018

1 reference

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

Targeting Src in breast cancer

21 January 2018

1 reference

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

21 January 2018

1 reference

Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection

21 January 2018

1 reference

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

21 January 2018

1 reference

BRCA1 dysfunction in sporadic basal-like breast cancer

21 January 2018

1 reference

Basal-like breast cancer and the BRCA1 phenotype

21 January 2018

1 reference

Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents

21 January 2018

1 reference

Single-strand interruptions in replicating chromosomes cause double-strand breaks

21 January 2018

1 reference

BRCA1 mutations in primary breast and ovarian carcinomas.

21 January 2018

1 reference

PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?

21 January 2018

1 reference

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

21 January 2018

1 reference

KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations

21 January 2018

1 reference

Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin

21 January 2018

1 reference

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

21 January 2018

1 reference

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

21 January 2018

1 reference

Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer

21 January 2018

1 reference

Docetaxel versus paclitaxel for antiangiogenesis

21 January 2018

1 reference

Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).

21 January 2018

1 reference

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

21 January 2018

1 reference

Protein biomarker identification in the CSF of patients with CNS lymphoma

21 January 2018

1 reference

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

21 January 2018

1 reference

Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer

21 January 2018

1 reference

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.09.68

1 reference

21 August 2017

1 reference

PubMed ID

19792970